Search

everythinglearnresearchcommunity

for

Search:↓

Targeting specific T cells may help treat alopecia areata.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

Alopecia areata is not linked to vitamin B12 deficiency.

A 22-year-old with multiple autoimmune diseases needs a multidisciplinary treatment approach.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Autoimmune Polyendocrine Syndromes involve specific combinations of autoimmune diseases.

Alopecia areata patients are more likely to develop systemic lupus erythematosus.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Tislelizumab can cause cutaneous lupus erythematosus.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

The case shows how hard it is to tell apart Multiple Autoimmune Syndrome from other similar autoimmune conditions, but correct diagnosis is key for treatment to work.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Alopecia areata patients may have higher T3 and cortisol levels, suggesting a hormonal link.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

People with alopecia areata often have low vitamin D levels, which may worsen their hair loss.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Higher levels of IL-1R1 and hsa-miR-19b-3p may help diagnose and predict alopecia areata severity.

Adalimumab can cause complete hair loss in rare cases.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Antituberculous drugs improved symptoms in a woman with lupus and myositis.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Epigenetic changes in blood cells may contribute to alopecia areata.